Hepatitis C virus (HCV) tends to associate preferentially with high-density lipoproteins by standard ultracentrifugal fractionation of plasma from patients with chronic HCV infection

被引:5
作者
Manzini, P [1 ]
Dusheiko, GM [1 ]
Brown, DJC [1 ]
Khakoo, SI [1 ]
Owen, JS [1 ]
机构
[1] Univ London, Royal Free Hosp, Sch Med, Dept Med, London NW3 2PF, England
关键词
chronic hepatitis C; HCV-RNA detection; plasma lipoproteins; polymerase chain reaction;
D O I
10.1016/S1386-6346(98)00027-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Because hepatitis C virus (HCV) has an unusually low buoyant density in plasma, we have determined whether HCV-RNA associates with specific lipoprotein classes by conventional NaCl-NaBr density solutions and whether the association is affected by viraemia. We studied 12 consecutive patients with chronic HCV and obtained four plasma lipoprotein fractions using sequential, isopycnic ultracentrifugation: very-low plus intermediate-density lipoproteins (VLDL/IDL; rho < 1.019 g ml(-1)), low-density lipoproteins (LDL; rho 1.019-1.063 g ml(-1)), high-density lipoproteins (HDL; rho 1.063-1.21 g ml(-1)) and very-high-density lipoproteins (rho > 1.21 g ml(-1), which also include bulk plasma proteins). HCV-RNA was determined in each fraction, and after two successive 10-fold dilutions, using a nested PCR of the 5' non-coding region. In 10 patients, HCV-RNA was detected in all samples, in one patient in only the HDL, and in the remaining patient in all fractions except LDL. This study confirms that HCV in plasma has a relatively low density and that much is lipoprotein associated. Moreover, we found that in most patients (9/12; 75%) the HDL fraction had the richest, or equal richest, concentration of HCV-RNA. Nevertheless, the virion clearly distributed heterogeneously in plasma, although no obvious relationship was noted between distribution patterns and either the level of viraemia or ongoing antiviral treatment. Whether this preference for association with HDL is mediated by the lipid or protein constituents of the HCV particle remains to be established. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:158 / 165
页数:8
相关论文
共 20 条
  • [1] HEPATITIS-C VIRUS - BUOYANT DENSITY OF THE FACTOR-VIII-DERIVED ISOLATE IN SUCROSE
    BRADLEY, D
    MCCAUSTLAND, K
    KRAWCZYNSKI, K
    SPELBRING, J
    HUMPHREY, C
    COOK, EH
    [J]. JOURNAL OF MEDICAL VIROLOGY, 1991, 34 (03) : 206 - 208
  • [2] CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
  • [3] CHARACTERISTICS OF THE BINDING OF HUMAN AND BOVINE HIGH-DENSITY-LIPOPROTEINS BY BLOOD-STREAM FORMS OF THE AFRICAN TRYPANOSOME, TRYPANOSOMA-BRUCEI-BRUCEI
    GILLETT, MPT
    OWEN, JS
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1123 (03) : 239 - 248
  • [4] GOTTO AM, 1986, METHOD ENZYMOL, V128, P3
  • [5] EQUILIBRIUM CENTRIFUGATION STUDIES OF HEPATITIS-C VIRUS - EVIDENCE FOR CIRCULATING IMMUNE-COMPLEXES
    HIJIKATA, M
    SHIMIZU, YK
    KATO, H
    IWAMOTO, A
    SHIH, JW
    ALTER, HJ
    PURCELL, RH
    YOSHIKURA, H
    [J]. JOURNAL OF VIROLOGY, 1993, 67 (04) : 1953 - 1958
  • [6] AVOIDING FALSE POSITIVES WITH PCR
    KWOK, S
    HIGUCHI, R
    [J]. NATURE, 1989, 339 (6221) : 237 - 238
  • [7] TRYPANOSOMA-BRUCEI-BRUCEI AND HIGH-DENSITY-LIPOPROTEINS - OLD AND NEW THOUGHTS ON THE IDENTITY AND MECHANISM OF THE TRYPANOCIDAL FACTOR IN HUMAN SERUM
    LORENZ, P
    BETSCHART, B
    OWEN, JS
    [J]. PARASITOLOGY TODAY, 1995, 11 (09): : 348 - 352
  • [8] APOLIPOPROTEIN-A-I INTERACTS WITH THE N-TERMINAL FUSOGENIC DOMAINS OF SIV (SIMIAN IMMUNODEFICIENCY VIRUS) GP32 AND HIV (HUMAN-IMMUNODEFICIENCY-VIRUS) GP41 - IMPLICATIONS IN VIRAL ENTRY
    MARTIN, I
    DUBOIS, MC
    SAERMARK, T
    RUYSSCHAERT, JM
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 186 (01) : 95 - 101
  • [9] HEPATITIS-B VIRUS SURFACE-ANTIGEN BINDS TO APOLIPOPROTEIN-H
    MEHDI, H
    KAPLAN, MJ
    ANLAR, FY
    YANG, X
    BAYER, R
    SUTHERLAND, K
    PEEPLES, ME
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (04) : 2415 - 2424
  • [10] Mills G.L.L., 1984, GUIDEBOOK LIPOPROTEI